1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy

Ticiana Leal, David Berz, Igor I. Rybkin, Wade T. Iams, Débora S. Bruno, Collin M. Blakely, Alexander I. Spira, Manish R. Patel, David Waterhouse, Donald Richards, Anthony Pham, Robert M. Jotte, Edward B. Garon, David S. Hong, Ronald Shazer, Xin Yan, L. Latven, Kai He